MX2022000439A - Terapia con linfocitos de infiltracion tumoral y sus usos. - Google Patents

Terapia con linfocitos de infiltracion tumoral y sus usos.

Info

Publication number
MX2022000439A
MX2022000439A MX2022000439A MX2022000439A MX2022000439A MX 2022000439 A MX2022000439 A MX 2022000439A MX 2022000439 A MX2022000439 A MX 2022000439A MX 2022000439 A MX2022000439 A MX 2022000439A MX 2022000439 A MX2022000439 A MX 2022000439A
Authority
MX
Mexico
Prior art keywords
patients
expression
biomarker
therapy
receptor
Prior art date
Application number
MX2022000439A
Other languages
English (en)
Inventor
Nicola Kaye Price
John Stephen Bridgeman
Original Assignee
Instil Bio Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instil Bio Uk Ltd filed Critical Instil Bio Uk Ltd
Publication of MX2022000439A publication Critical patent/MX2022000439A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7156—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2312—Interleukin-12 (IL-12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Abstract

La presente invención se refiere a un biomarcador útil en terapia celular adoptiva. El biomarcador en cuestión es CD150, también denominado SLAM o SLAMF1. En la presente, los solicitantes demuestran que la expresión de CD150 en productos para infusión de linfocitos de infiltración tumoral tiene correlación con la tasa de respuesta observada en dichos pacientes. Se observa una expresión elevada de CD150 en pacientes que logran una respuesta completa y una baja expresión en pacientes sin respuesta a la terapia. La invención hace referencia al uso del biomarcador para predecir la tasa de respuesta o estratificar a los pacientes para el tratamiento. También abarca la explotación de este receptor en regímenes de terapia celular adoptiva en general, incluidas, de modo no taxativo, la sobreexpresión del receptor en poblaciones de linfocitos T o el aislamiento de las células con expresión de CD150, en un intento de aumentar la eficacia.
MX2022000439A 2019-07-24 2020-07-24 Terapia con linfocitos de infiltracion tumoral y sus usos. MX2022000439A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962878001P 2019-07-24 2019-07-24
GBGB1910605.3A GB201910605D0 (en) 2019-07-24 2019-07-24 Tumour infltracting lymphocyte therapy amd uses thereo
PCT/GB2020/051790 WO2021014174A1 (en) 2019-07-24 2020-07-24 Tumour infiltrating lymphocyte therapy and uses thereof

Publications (1)

Publication Number Publication Date
MX2022000439A true MX2022000439A (es) 2022-08-15

Family

ID=67839864

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000439A MX2022000439A (es) 2019-07-24 2020-07-24 Terapia con linfocitos de infiltracion tumoral y sus usos.

Country Status (17)

Country Link
US (1) US20220378826A1 (es)
EP (1) EP4003372A1 (es)
JP (1) JP2022541523A (es)
KR (1) KR20220041839A (es)
CN (1) CN114174495A (es)
AU (1) AU2020316708A1 (es)
BR (1) BR112022001139A2 (es)
CA (1) CA3142913A1 (es)
CL (1) CL2022000152A1 (es)
CO (1) CO2021018066A2 (es)
CR (1) CR20220027A (es)
EC (1) ECSP22004616A (es)
GB (1) GB201910605D0 (es)
IL (1) IL289235A (es)
MX (1) MX2022000439A (es)
PE (1) PE20220258A1 (es)
WO (1) WO2021014174A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
CN109536444B (zh) * 2018-12-11 2022-06-28 吉林省拓华生物科技有限公司 一种适用于恶性实体瘤肿瘤浸润t淋巴细胞的分离诱导方法
GB201900858D0 (en) * 2019-01-22 2019-03-13 Price Nicola Kaye Receptors providing targeted costimulation for adoptive cell therapy
WO2021123832A1 (en) 2019-12-20 2021-06-24 Instil Bio (Uk) Limited Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof
EP4314342A1 (en) * 2021-03-23 2024-02-07 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Antigen reactive t-cell receptors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4365196A (en) * 1994-12-02 1996-06-19 Schering Corporation Purified genes encoding mammalian cell surface antigens; proteins and antibodies
AU2002240818C1 (en) * 2001-03-14 2008-11-06 Agilent Technologies, Inc. MHC molecule constructs and their uses for diagnosis and therapy
EP3099704B1 (en) * 2014-01-27 2021-03-17 Molecular Templates, Inc. Mhc class i epitope delivering polypeptides
WO2017179015A1 (en) * 2016-04-15 2017-10-19 Glaxosmithkline Intellectual Property Development Limited Compositions for the treatment of cancer
GB201801067D0 (en) * 2018-01-23 2018-03-07 Price Nicola Kaye Biomarkers predictive of tumour infiltrating lymphocyte therapy and uses thereof
CN113899903A (zh) * 2020-07-06 2022-01-07 上海市免疫学研究所 结直肠癌生物标志物及其在诊断、预防、治疗及预后中的应用
CN116769729A (zh) * 2023-06-05 2023-09-19 中国科学技术大学 靶向cd150的抗体或抗原结合片段及其应用

Also Published As

Publication number Publication date
EP4003372A1 (en) 2022-06-01
IL289235A (en) 2022-02-01
BR112022001139A2 (pt) 2022-03-15
GB201910605D0 (en) 2019-09-04
CA3142913A1 (en) 2021-01-28
KR20220041839A (ko) 2022-04-01
JP2022541523A (ja) 2022-09-26
AU2020316708A1 (en) 2022-03-03
US20220378826A1 (en) 2022-12-01
PE20220258A1 (es) 2022-02-21
CL2022000152A1 (es) 2022-10-07
WO2021014174A1 (en) 2021-01-28
CN114174495A (zh) 2022-03-11
CO2021018066A2 (es) 2022-02-07
ECSP22004616A (es) 2022-02-25
CR20220027A (es) 2022-02-25

Similar Documents

Publication Publication Date Title
PH12020551110A1 (en) Biomarker predictive of tumour infiltrating lymphocyte therapy and uses thereof
CR20220027A (es) Terapia con linfocitos de infiltración tumoral y sus usos
EA036698B9 (ru) Моноклональное антитело против lif человека и его применение для лечения рака с высоким уровнем lif
BR112016023523A2 (pt) produtos de células t modificados em gene de composição definida
WO2012156958A8 (en) Cell line of lymphocytes comprising gamma-delta t cells, composition and production method thereof
NZ609594A (en) Eph receptor expression in tumor stem cells
NZ602515A (en) Proteins that bind pi16 and uses thereof
Beider et al. Upregulation of senescent/exhausted phenotype of CAR T cells and induction of both treg and myeloid suppressive cells correlate with reduced response to CAR T cell therapy in relapsed/refractory B cell malignancies
MX2021014963A (es) Metodos para predecir el beneficio terapeutico de la terapia con anti-cd19 en pacientes.
MX2015008190A (es) Tretaspanina 33 es una candidata para la terapia dirigida de anticuerpos para el tratamiento de linfomas de hodgkin de linfocitos b.
ZA201907369B (en) Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
MX2018011169A (es) Metodo para prevenir la enfermedad del injerto contra huesped.
Jia et al. TIGIT expression positively associates with NK cell function in AML patients
EA202193024A1 (ru) Анти-cd19-терапия у пациентов с ограниченным числом естественных клеток-киллеров
BR112021018684A2 (pt) Métodos para aumentar a eficiência de esgotamento de células tcr¿¿+
Tsirigotis et al. Natural killer cell cytotoxicity is a predictor of outcome for patients with high risk myelodysplastic syndrome and oligoblastic acute myeloid leukemia treated with azacytidine
Fioranelli et al. Theoretical-Scientific Foundations about the Use of Low-Dose in Oncology
MX2021010274A (es) Celulas, composiciones y metodos para mejorar la funcion inmune.
Martner et al. Natural Killer Cell Expression of Natural Cytotoxicity Receptors Determines Relapse Risk in Elderly Patients with Acute Myeloid Leukemia Receiving Immunotherapy with Histamine Dihydrochloride and Interleukin-2
Sutherland Understanding the Fluctuations in Immune Cell Populations
Hoffmann et al. Marked Impact of Different Cytokines on Phenotype and Cytotoxic Activity of CD19-Specific CAR T Cells
Chin et al. A safe and simple approach to obtaining sufficient cytokine induced killer (CIK) cells from critically-ill cancer patients without the need for apheresis or peripheral mobilization
Schumacher et al. Treatment response of advanced HNSCC towards immune checkpoint inhibition is associated with an activated effector memory T cell phenotype
Flaherty et al. The role of psychological stress and nitric oxide synthase inhibition in breast cancer
Trilla et al. Cost analysis of cardiac transplantation in a Spanish hospital